Lv4
466 积分 2025-07-17 加入
PD-1 blockade unleashes local hepatitis B virus-related B cell response inhibiting hepatocellular carcinoma
7天前
已完结
EGFR-targeting ADCs: From oncogene addiction to antigen-guided drug delivery
7天前
已完结
Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial
13天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
16天前
已完结
Antibody-drug conjugate design and mechanisms of action for cancer treatment: state of the art and beyond
16天前
已完结
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics
16天前
已完结
TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer
1个月前
已完结
The cartography of KRAS inhibitor resistance in colorectal cancer
1个月前
已完结
Abstract LB260: Potential prognostic/predictive biomarkers for sacituzumab govitecan in EVOKE-01
2个月前
已关闭
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non–Small Cell Lung Cancer
2个月前
已完结
皖公网安备34019202002308
